Edition:
United Kingdom

People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

43.98USD
25 Jun 2019
Change (% chg)

$0.63 (+1.45%)
Prev Close
$43.35
Open
$43.50
Day's High
$44.91
Day's Low
$43.00
Volume
93,514
Avg. Vol
169,535
52-wk High
$66.26
52-wk Low
$22.23

Subramanian, Kala 

Dr. Kala Subramanian, Ph.D., has been Senior Vice President - Strategic Development and Operations of CRISPR Therapeutics Ltd since June 2016. Prior to joining the Company, Dr. Subramanian served as Global Head of Strategic Development & Program Management in Oncology Development at Novartis Pharmaceutical Corporation, from December 2003 to June 2016. Prior to that, Dr. Subramanian served as Senior Project Manager at Millennium Pharmaceuticals, from May 2001 to December 2003. Dr. Subramanian also served as Senior Consultant at Accenture Consulting, from May 1998 to April 2001. Dr. Subramanian received a Ph.D. in Chemistry from Cornell University and a M.Sc. in Chemistry from Indian Institute of Technology, Madras (India). She completed post-doctoral work at Duke University Medical Center.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --